GlassScriptPhysician profile
Reshma Patel
NPI 1639420540
$3,336.56
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $484 · 2021: $275 · 2022: $547 · 2023: $210 · 2024: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,846.52 | 2019-2024 | Repatha, Enbrel, Tavneos |
| Novartis Pharmaceuticals Corporation | $290.06 | 2019-2024 | |
| Pfizer INC. | $229.79 | 2019-2024 | |
| Glaxosmithkline, LLC. | $150.84 | 2023-2024 | Benlysta |
| Medexus Pharma, INC. | $132.68 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $125.69 | 2019-2024 | Orencia |
| Genentech USA, INC. | $100.11 | 2019-2020 | |
| Abbvie INC. | $88.70 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $80.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $67.20 | 2024 | Saphnelo |
| Genentech, INC. | $49.95 | 2021 | |
| Allergan, INC. | $35.79 | 2020 | |
| Azurity Pharmaceuticals, INC. | $28.22 | 2024 | Xatmep |
| Biocon Biologics INC | $28.07 | 2024 | Hulio |
| Alexion Pharmaceuticals, INC. | $24.61 | 2024 | Strensiq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.77 | 2024 | Cyltezo |
| Csl Behring | $21.79 | 2019 | |
| Masimo Corporation | $13.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.